Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech Inc. demonstrated robust growth in its surgical soft tissue repair products, with a 24% year-over-year sales increase to $23.4 million, attributed to heightened demand for its key offerings. Additionally, the company reported continued revenue growth with an anticipated increase of 13-17% for 2026, supported by a new contract with Vizient, enhancing market access and distribution efficiency. With a focus on operational improvements and the achievement of profitability in third-quarter 2025, Sanara MedTech's strategic initiatives position it favorably for future financial performance.

Bears say

Sanara MedTech Inc reported net revenue of $26.3 million, reflecting a year-over-year growth of 21.5% but falling short of projections, highlighting concerns about sustained revenue growth potential. The company faces substantial risks, including the possibility of lower-than-expected revenue growth, challenges in acquiring new customers, and difficulties in launching new products, which could further affect its financial performance. Additionally, the reduction of the EV/Revenue multiple from 4.3x to 3.0x indicates negative adjustments in market expectations due to the exclusion of telehealth from its business model.

SMTI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Strong Buy based on their latest research and market trends.

According to 1 analysts, SMTI has a Strong Buy consensus rating as of Apr 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.